$28.99
-0.37 (-1.26%)
VKTX News4 articles
Viking Therapeutics Faces Cash Runway Questions Ahead of Q2 Report
Viking Therapeutics shares fell 6.2% last week as analysts increased Q2 loss estimates by 24% to $1.23 per share. The company's cash runway faces scrutiny ahead of earnings on July 29.
Viking Therapeutics Holds Phase 3 Focus Despite Weekly Stock Dip
Viking Therapeutics shares declined 4.6% over the past week, yet its valuation premium over Structure Therapeutics persists, reflecting continued investor confidence in its Phase 3 obesity programs.
Eli Lilly's $50 Obesity Drug Strategy: Volume vs. Price
Eli Lilly's stock hovers near record highs as a new Medicare program offers $50/month access to its obesity drugs. First-quarter revenue surged 56%, but lower realized prices trimmed growth.
Viking Therapeutics Surges on Obesity Drug Hopes
Viking Therapeutics shares climbed 6% to $34.30 as investors bet on upcoming Phase 3 data for its obesity drug VK2735, expected in Q3 2026.